Antisense knockdown of Kras inhibits fibrosis in a rat model of unilateral ureteric obstruction.

Autor:	Wang JH; Department of Renal Medicine, King's College Hospital, London, United Kingdom., Newbury LJ, Knisely AS, Monia B, Hendry BM, Sharpe CC
Jazyk:	angličtina
Zdroj:	The American journal of pathology [Am J Pathol] 2012 Jan; Vol. 180 (1), pp. 82-90. Date of Electronic Publication: 2011 Nov 07.
DOI:	10.1016/j.ajpath.2011.09.036
Abstrakt:	Tubulointerstitial fibrosis is the hallmark of chronic kidney disease and is characterized by an increase in the number and activity of interstitial fibroblasts and by excessive matrix deposition. Ras is an intracellular signaling molecule involved in cell proliferation and differentiation. It has recently been implicated in the pathogenesis of renal fibrosis. Of the three different isoforms of Ras (Kirsten, Harvey, and Neural), we previously demonstrated that the Kirsten isoform is key in the control of renal fibroblast proliferation in vitro. In this study, we used gene therapy in the form of antisense oligonucleotides (ASOs) specifically to silence Kras (alias Ki-ras) expression in a rat model of renal fibrosis caused by unilateral ureteric obstruction. We demonstrate that renal Kras expression increases by 70% in this model compared with sham-operated animals and that treatment with ASOs can reduce total renal Kras by >90% to levels well below basal. This silencing is associated with a dramatic inhibition of interstitial fibrosis, a fivefold reduction in α-smooth muscle actin expression, and a 2.4-fold reduction in collagen I deposition. This inhibition was observed despite histologic evidence of marked interstitial inflammation. These findings demonstrate that silencing Kras expression can markedly inhibit renal fibrosis. This strategy should be considered as a new potential therapeutic avenue. (Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu